Haymarket names Barsamian med-ed unit head

Share this article:
Dik Barsamian joined Haymarket as executive VP in charge of Haymarket Medical Education LP. Haymarket, a non-accredited provider, partners with medical schools to deliver educational programming and publications. Before coming to Haymarket, Barsamian was head of Thomson Medical Education, the division of Thomson Healthcare which was sold in April to private equity firm ABRY Partners for an undisclosed sum and renamed KnowledgePoint360. He replaces David Helgans, who left Haymarket to become president of CME Scholar, part of Grey Healthcare Group’s International Meetings & Science. Barsamian said he will look to build on his new company’s therapeutic expertise in a number of areas, including pediatric and women’s health education, as well as its ability to deliver education in innovative ways. “One of Haymarket’s strengths is its diverse in-house expertise and ability to leverage varied communications channels, including Web, handheld and print delivery vehicles,” he told MM&M. “These capabilities are very important to meet the educational needs of healthcare professionals in what is a dynamic and evolving medical education arena.” (Haymarket Medical Education and Haymarket Business Media, publisher of MM&M, are both divisions of Haymarket Media Group.) A longtime manager with extensive sales and marketing experience, Barsamian spent 15 years at Thomson. His senior management roles there included manager of the PDR sales and marketing operation. Most recently he was general manager of Physicians World, Gardiner-Caldwell, Scientific Connexions and Professional Postgraduate Services, Thomson’s promotional education, publications planning and accredited education businesses. In his new role, he will work out of Haymarket Medical’s Montvale, NJ, office and report to Lee Maniscalco, CEO of Haymarket Medical. “Dik’s strong knowledge of drug information and CME will prove to be invaluable, as it aligns perfectly with our core medical businesses of Monthly Prescribing Reference and the Montvale group,” said Maniscalco. Prior to his career at Thomson, Barsamian spent four years as an AstraZeneca sales rep.
Share this article:
close

Next Article in News

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.